A review approach of Alzheimer Disease and Pharmacological Management

  • Posted on: 31 October 2017
  • By: admin

 

Magazine Home


November 2017 ARTICLE LIST >>

PharmaTutor (November - 2017)

 

ISSN: 2347 - 7881
(Volume 5, Issue 11)

 

Received On: 02/08/2017; Accepted On: 02/08/2017; Published On: 01/11/2017

 

AUTHORS:
Senthamil Selvan T
Pharmaceutical Technical service department,
Mylan Laboratories Limited, Tamilnadu, India
pharmtamil@gmail.com

 

 

ABSTRACT:
Dementia is a chronic progressive disorder mainly causes the memory loss and cognitive dysfunction due to neurodegeneration. It is popularly known as Alzheimer disease. It is the fifth disorder leads to death. Those who are the people have crossed age 60 years risk chance of cause. Dementia the disorder is widely known as Alzheimer’s disease, senile dementia, vascular Dementia, Dementia with levy bodies, Parkinson’s disease, Frontotemporal dementia. By neurological examination like CT, MRI, and Spinal fluid analysis can occasionally be justified to confirm the dementia syndrome. For the AD the treatment are broadly takes place as two types, one is cognitive symptoms treatment, another Non- cognitive symptoms treatment. In that case for cognitive sign treatment cholinesterase inhibitors (such as Donepezil, rivastigmine), NMDA receptor inhibitors (Memantine) are used. Anti-psychotics’, Anti-depressant category drugs are used for Non-cognitive symptoms treatment.

 

 

How to cite this article: Senthamil ST; A review approach of Alzheimer Disease and Pharmacological Management; PharmaTutor; 2017; 5(11); 53-57

 

[ABSTRACT WITH CITATION]   [VIEW AS HTML